Lumaegis

Lumaegis

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Lumaegis is a private, pre-revenue medical technology company developing the RadBox™, a novel system for surgical instrument sterilization. Operating in the drug delivery and small molecule sectors, the company aims to address critical challenges in infection control within surgical environments. Based in San Diego and founded in 2018, it is currently in a pre-commercial stage, with its technology not yet available for sale or distribution in the USA. The company's value proposition centers on enhancing safety, efficacy, and sustainability in sterile processing.

Infection ControlHealthcare-Associated Infections

Technology Platform

RadBox™ system for surgical instrument sterilization, likely integrating a physical device with radiative (light-based) and/or small molecule-based disinfection technology.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

Large and growing global market for infection control driven by rising surgical volumes and heightened focus on HAIs.
Significant need for a rapid, low-temperature, and sustainable sterilization alternative to preserve expensive, delicate surgical instruments.
Potential for premium pricing and strong ROI argument for healthcare facilities.

Risk Factors

High technical and regulatory risk in proving sterilization efficacy and obtaining FDA clearance.
Challenging market adoption against entrenched, low-cost standard methods.
Financial dependency on external funding with no current revenue.

Competitive Landscape

Competes against large, established medical device companies like STERIS, Getinge, and Johnson & Johnson (ASP) that dominate the hospital sterilization equipment market. Also competes with alternative low-temperature technologies like hydrogen peroxide plasma and ozone systems. Differentiation must be clear on speed, instrument compatibility, and sustainability.